Omicron: Genome sequencing of samples from all Covid cases starts in Delhi

Genome sequencing of samples of all Covid-19-infected people in Delhi began Wednesday to ascertain if the new Omicron variant has spread in the community, city Health Minister Satyendar Jain said

Passengers arriving from Singapore on December 2 wait for their transport at the Delhi airport that has stepped up monitoring for Covid-19 after the Omicron variant of the virus was first detected in South Africa. (PTI Photo/Arun Sharma)
Press Trust of India New Delhi
2 min read Last Updated : Dec 22 2021 | 2:49 PM IST

Genome sequencing of samples of all COVID-19-infected people in Delhi began Wednesday to ascertain if the new Omicron variant has spread in the community, city Health Minister Satyendar Jain said.

The national capital is recording around 100-125 cases a day, while it has the capacity of genome sequencing of 400-500 samples daily.

"The Delhi government-run labs at the Lok Nayak Hospital and the Institute of Liver and Biliary Sciences can sequence 100 samples each day. Two Centre-run labs in Delhi can sequence 200-300 samples a day. So, 400-500 samples can be analysed in a day, Jain said.

"Around 100 to 125 new cases are emerging every day.... Samples of all COVID-19 patients will be sequenced from Wednesday. Through this, we will be able to ascertain the number of cases from the society. Till now, the maximum number of (Omicron) cases have come from foreign countries (sic)," he told reporters.

Jain had said Tuesday that three Omicron patients in Delhi had no travel history.

The total number of Omicron cases in the national capital mounted to 54, according to data shared by the Union Health Ministry on Tuesday.

Following a meeting of the Delhi Disaster Management Authority on Monday, Chief Minister Arvind Kejriwal had announced that samples of all Covid-positive patients would be sent for genome sequencing.

Minister Jain said the government will take steps to prevent crowding during Christmas and New Year's Eve celebrations.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Dec 22 2021 | 2:35 PM IST

Next Story